Lindblad Expeditions vs Strata Critical Medical
LIND and SRTA side by side, both in transportation services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How LIND and SRTA compare
Lindblad Expeditions is the larger company, worth 4.7 times as much as Strata Critical Medical ($2.3B against $487M).
Strata Critical Medical grew revenue faster over the last twelve months (66.8% versus 18.3% for Lindblad Expeditions).
Strata Critical Medical keeps more of each dollar of sales as profit, with a net margin of 15.7% compared with −2.1% at Lindblad Expeditions.
Strata Critical Medical scores higher on the StockData Score (17 against 7 for Lindblad Expeditions), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | LIND | SRTA |
|---|---|---|
| Size and price | ||
| Market cap | $2.3B | $487M |
| Share price | $34.55 | $5.51 |
| Change, 1 year | 181% | 8.0% |
| Change, 5 years | 112% | −43.0% |
| Beta (5Y) | 2.13 | 1.63 |
| Employees | 1,550 | 601 |
| StockData Score | ||
| Total score | 7 | 17 (better) |
| Valuation score | 0 | 4 (better) |
| Growth score | 4 | 4 |
| Performance score | 2 | 3 (better) |
| Health score | 1 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 10.8× |
| P/S | 2.7× | 1.9× (better) |
| P/B | – | 1.7× |
| EV/EBITDA | 20.6× | – |
| P/FCF | 20.8× | – |
| FCF yield | 4.8% (better) | −9.9% |
| Fair value | – | $8.72 |
| Margin of safety | – | 36.8% |
| Growth | ||
| Revenue growth (TTM) | 18.3% | 66.8% (better) |
| Revenue growth, 5Y average | 56.4% (better) | 44.6% |
| Profitability | ||
| Gross margin | 46.6% (better) | 20.6% |
| Operating margin | 7.0% (better) | −8.0% |
| Net margin | −2.1% | 15.7% (better) |
| FCF margin | 13.1% (better) | −18.9% |
| Return on equity | – | 16.0% |
| Return on invested capital | 29.4% (better) | −8.8% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Net debt / EBITDA | 2.72 | – |
| Current ratio | 0.84 | 2.64 (better) |
| Altman Z-score | 1.47 | 5.67 (better) |
| Piotroski F-score | 7 (better) | 5 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 80.3% | 63.0% |
| Held by insiders | 25.7% | 21.0% |
| Insider net buying, 12 months | −$61.5M | −$724K (better) |
| Superinvestors holding | – | 1 |
| Short interest, % of float | 10.7% | 6.5% |
Go deeper
- LIND stock overview
- LIND income statement
- LIND valuation and score
- SRTA stock overview
- SRTA income statement
- SRTA valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.